ERAP1 and inflammatory bowel disease: These findings indicate that partial ERAP1 deficiency disrupts immune homeostasis and reduces the therapeutic efficacy of sulfasalazine, underscoring ERAP1 as a potential target for inflammatory bowel disease intervention.